Ziarco Pharma
Ziarco Pharma was a UK biotechnology company developing treatments for inflammatory skin diseases. Novartis acquired the company in January 2017. Its lead investigational drug, adriforant (ZPL389), targeted the histamine H4 receptor; Novartis discontinued development in 2020.
Key facts
| Company Operating Status | Acquired |
|---|---|
| Wellfound ID | ziarco-pharma |